BRANDI PAUGH: Open Payments
NPI 1982104360 · OAKLAND, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$454 in 24 payments from 8 companies in 2025. Trend: 2023 $688 · 2024 $633 · 2025 $454
Food & beverage: $454
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 9 | $155 |
| Astellas Pharma US Inc | 7 | $147 |
| Novo Nordisk Inc | 2 | $46 |
| Currax Pharmaceuticals LLC | 2 | $32 |
| GlaxoSmithKline, LLC. | 1 | $24 |
| Lilly USA, LLC | 1 | $19 |
| ABBVIE INC. | 1 | $17 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $14 |
Products named: Veozah, AIRSUPRA, FARXIGA, JARDIANCE, Ozempic, TRELEGY ELLIPTA, BREZTRI, Rybelsus.
Industry payments across MD — which companies pay providers there.
